Navigation Links
Genomma Lab Internacional Revises 2009 Earnings Guidance
Date:9/8/2009

MEXICO CITY, Sept. 8 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of the fastest growing pharmaceutical and personal care products companies in Mexico with expansion into the international markets, announced today revisions to its earnings guidance for the full year of 2009. The Company expects net sales growth in the range of 35%-38% and an EBITDA margin of approximately 25%.

The revision of the Company's expected sales growth is mainly due to the higher sales anticipated from launches of the Company's recent acquisitions, namely Primer Nivel Por tu Salud(R), combined with a positive trend in demand for our base products in Mexico and in our existing international operations.

The Company is also slightly lowering its expected EBITDA margin due to the significant advertising investment required during the first months of a product launch. Once these launches stabilize, Genomma Lab expects their profitability margins to be in line with those of the rest of its portfolio.

It is important to highlight that this guidance revision is not contemplating sales from any geographic expansion of the Company's operations.

Genomma Lab will report third quarter results on October 26, 2009 and host a quarterly conference call the following business day.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico with an increasing presence in the international markets. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low- cost, highly flexible operating model.

Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:                          In New York:
    Oscar Villalobos-Torres           i-advize Corporate Communications, Inc.
    Tel: +52 55 5081-0000 Ext. 5106   Tel. (212) 406 3692
    e-mail: inversion@genommalab.co   e-mail: genommalab@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Internacional Acquires UNIGASTROZOL
4. Genomma Lab Announces 2009 Earnings Guidance
5. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
6. Genomma Lab Announces Initiation of Stock Repurchase Fund
7. Genomma Lab, New Participant in Market-Maker Program
8. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
9. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
10. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
11. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that ... New Product Innovation Award for Its fibromyalgia pain management ... medical device market research by Frost & Sullivan,s industry experts. ... pain relief product, the AVACEN 100, offers a safe and ... pain. ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
Breaking Medicine Technology: